149 related articles for article (PubMed ID: 30955980)
1. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.
El Sahly HM; Atmar RL; Patel SM; Bellamy A; Liu L; Hong W; Zhu H; Guan Y; Keitel WA;
Vaccine; 2019 May; 37(19):2561-2568. PubMed ID: 30955980
[TBL] [Abstract][Full Text] [Related]
2. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.
Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR
JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184
[TBL] [Abstract][Full Text] [Related]
3. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.
Babu TM; Levine M; Fitzgerald T; Luke C; Sangster MY; Jin H; Topham D; Katz J; Treanor J; Subbarao K
Vaccine; 2014 Nov; 32(50):6798-804. PubMed ID: 25446831
[TBL] [Abstract][Full Text] [Related]
4. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
[TBL] [Abstract][Full Text] [Related]
5. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
6. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine.
El Sahly HM; Makedonas G; Corry D; Atmar RL; Bellamy A; Cross K; Keitel WA
Hum Vaccin Immunother; 2020 Dec; 16(12):3138-3145. PubMed ID: 32401699
[TBL] [Abstract][Full Text] [Related]
8. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses.
Zhang L; Jia N; Li J; Han Y; Cao W; Wang S; Huang Z; Lu S
Hum Vaccin Immunother; 2014; 10(7):1949-58. PubMed ID: 25424804
[TBL] [Abstract][Full Text] [Related]
9. H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.
Khurana S; Coyle EM; Verma S; King LR; Manischewitz J; Crevar CJ; Carter DM; Ross TM; Golding H
Vaccine; 2014 Nov; 32(48):6421-32. PubMed ID: 25284811
[TBL] [Abstract][Full Text] [Related]
10. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans.
Chung KY; Coyle EM; Jani D; King LR; Bhardwaj R; Fries L; Smith G; Glenn G; Golding H; Khurana S
Vaccine; 2015 Jul; 33(32):3953-62. PubMed ID: 26093202
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an inactivated cell culture-derived H7N9 influenza vaccine in healthy adults: A phase I/II, prospective, randomized, open-label trial.
Wu UI; Hsieh SM; Lee WS; Wang NC; Kung HC; Ou TY; Chen FL; Lin TY; Chen YC; Chang SC
Vaccine; 2017 Jul; 35(33):4099-4104. PubMed ID: 28668573
[TBL] [Abstract][Full Text] [Related]
12. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
[TBL] [Abstract][Full Text] [Related]
13. Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes.
Prabakaran M; Kumar SR; Raj KV; Wu X; He F; Zhou J; Kwang J
Antiviral Res; 2014 Sep; 109():149-59. PubMed ID: 24997413
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
Nolan T; Izurieta P; Lee BW; Chan PC; Marshall H; Booy R; Drame M; Vaughn DW
J Infect Dis; 2014 Dec; 210(11):1800-10. PubMed ID: 24973461
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults.
Jackson LA; Stapleton JT; Walter EB; Chen WH; Rouphael NG; Anderson EJ; Neuzil KM; Winokur PL; Smith MJ; Schmader KE; Swamy GK; Thompson AB; Mulligan MJ; Rostad CA; Cross K; Tsong R; Wegel A; Roberts PC
Vaccine; 2024 Jan; 42(2):295-309. PubMed ID: 38105137
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses.
Kwon HI; Kim YI; Park SJ; Song MS; Kim EH; Kim SM; Si YJ; Lee IW; Song BM; Lee YJ; Yun SJ; Kim WJ; Choi YK
J Virol; 2017 Jun; 91(11):. PubMed ID: 28331080
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting protective immunity against H7N9 infection is induced by intramuscular or CpG-adjuvanted intranasal immunization with the split H7N9 vaccine.
Zhou Y; Li S; Bi S; Li N; Bi Y; Liu W; Wang B
Int Immunopharmacol; 2020 Jan; 78():106013. PubMed ID: 31806571
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults.
Rostad CA; Atmar RL; Walter EB; Frey S; Meier JL; Sherman AC; Lai L; Tsong R; Kao CM; Raabe V; El Sahly HM; Keitel WA; Whitaker JA; Smith MJ; Schmader KE; Swamy GK; Abate G; Winokur P; Buchanan W; Cross K; Wegel A; Xu Y; Yildirim I; Kamidani S; Rouphael N; Roberts PC; Mulligan MJ; Anderson EJ
Clin Infect Dis; 2024 Mar; ():. PubMed ID: 38537255
[TBL] [Abstract][Full Text] [Related]
19. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials.
Feldman RA; Fuhr R; Smolenov I; Mick Ribeiro A; Panther L; Watson M; Senn JJ; Smith M; Almarsson Ӧ; Pujar HS; Laska ME; Thompson J; Zaks T; Ciaramella G
Vaccine; 2019 May; 37(25):3326-3334. PubMed ID: 31079849
[TBL] [Abstract][Full Text] [Related]
20. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes.
Mallett CP; Beaulieu E; Joly MH; Baras B; Lu X; Liu F; Levine MZ; Katz JM; Innis BL; Giannini SL
Vaccine; 2015 Jul; 33(32):3784-7. PubMed ID: 26100923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
